U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07386704) titled 'Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer' on Jan. 27.
Brief Summary: This study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer. The study will evaluate the efficacy and safety of nintedanib combined with radiotherapy and chemotherapy (gemcitabine or capecitabine monotherapy). The primary endpoint of this study is the 1-year local control rate (LCR).
Study Start Date: Dec. 09, 2025
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer Non-resectable
I...